Cargando…

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

Detalles Bibliográficos
Autores principales: Chai, Sanbao, Yu, Shuqing, Liu, Fengqi, Liu, Zuoxiang, Yang, Qingqing, Sun, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106192/
https://www.ncbi.nlm.nih.gov/pubmed/36723862
http://dx.doi.org/10.1097/CM9.0000000000002520
_version_ 1785026375537655808
author Chai, Sanbao
Yu, Shuqing
Liu, Fengqi
Liu, Zuoxiang
Yang, Qingqing
Sun, Feng
author_facet Chai, Sanbao
Yu, Shuqing
Liu, Fengqi
Liu, Zuoxiang
Yang, Qingqing
Sun, Feng
author_sort Chai, Sanbao
collection PubMed
description
format Online
Article
Text
id pubmed-10106192
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101061922023-04-17 Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model Chai, Sanbao Yu, Shuqing Liu, Fengqi Liu, Zuoxiang Yang, Qingqing Sun, Feng Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2023-01-05 2023-02-01 /pmc/articles/PMC10106192/ /pubmed/36723862 http://dx.doi.org/10.1097/CM9.0000000000002520 Text en Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Correspondence
Chai, Sanbao
Yu, Shuqing
Liu, Fengqi
Liu, Zuoxiang
Yang, Qingqing
Sun, Feng
Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title_full Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title_fullStr Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title_full_unstemmed Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title_short Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
title_sort benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106192/
https://www.ncbi.nlm.nih.gov/pubmed/36723862
http://dx.doi.org/10.1097/CM9.0000000000002520
work_keys_str_mv AT chaisanbao benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel
AT yushuqing benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel
AT liufengqi benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel
AT liuzuoxiang benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel
AT yangqingqing benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel
AT sunfeng benefitriskassessmentofincretinandotherantidiabeticagentsintype2diabetesusingastochasticmulticriteriaacceptabilityanalysismodel